Cytokinetics, Incorporated
CYTK
$59.32
-$0.68-1.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.89% | 318.14% | 26,714.86% | 89.10% | 912.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.89% | 318.14% | 26,714.86% | 89.10% | 912.38% |
| Cost of Revenue | 11.50% | 17.28% | 41.40% | 22.40% | 10.18% |
| Gross Profit | -12.96% | -15.62% | 42.30% | -21.71% | 7.93% |
| SG&A Expenses | 47.14% | 22.60% | 29.31% | 26.09% | 41.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.75% | 19.42% | 36.69% | 23.72% | 20.82% |
| Operating Income | -28.28% | -18.43% | 14.34% | -23.29% | -9.12% |
| Income Before Tax | -22.00% | -90.71% | 6.24% | -18.97% | -9.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.00% | -90.71% | 6.24% | -18.97% | -9.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.00% | -90.71% | 6.24% | -18.97% | -9.59% |
| EBIT | -28.28% | -18.43% | 14.34% | -23.29% | -9.12% |
| EBITDA | -28.43% | -18.56% | 14.51% | -23.75% | -12.86% |
| EPS Basic | -19.95% | -87.06% | 14.27% | -2.34% | 8.06% |
| Normalized Basic EPS | 59.51% | -87.06% | 14.27% | -2.33% | 8.06% |
| EPS Diluted | -19.95% | -87.06% | 14.27% | -2.34% | 8.06% |
| Normalized Diluted EPS | 59.51% | -87.06% | 14.27% | -2.33% | 8.06% |
| Average Basic Shares Outstanding | 1.72% | 1.95% | 9.35% | 16.26% | 19.19% |
| Average Diluted Shares Outstanding | 1.72% | 1.95% | 9.35% | 16.26% | 19.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |